Level Four Advisory Services LLC Purchases New Position in 10x Genomics $TXG

Level Four Advisory Services LLC acquired a new position in 10x Genomics (NASDAQ:TXG) during the 3rd quarter, HoldingsChannel reports. The fund acquired 54,751 shares of the company’s stock, valued at approximately $640,000.

Several other institutional investors have also recently made changes to their positions in the company. Foundations Investment Advisors LLC purchased a new stake in 10x Genomics during the third quarter worth $665,000. Jump Financial LLC boosted its stake in shares of 10x Genomics by 130.2% during the 2nd quarter. Jump Financial LLC now owns 1,041,051 shares of the company’s stock worth $12,055,000 after acquiring an additional 588,769 shares in the last quarter. AlphaQuest LLC boosted its stake in shares of 10x Genomics by 234.3% during the 3rd quarter. AlphaQuest LLC now owns 133,419 shares of the company’s stock worth $1,560,000 after acquiring an additional 93,514 shares in the last quarter. Friedenthal Financial acquired a new stake in shares of 10x Genomics during the 3rd quarter valued at about $924,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of 10x Genomics in the 3rd quarter valued at about $1,179,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

10x Genomics Trading Down 3.8%

TXG opened at $20.81 on Friday. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $23.56. The firm has a market capitalization of $2.66 billion, a PE ratio of -59.46 and a beta of 2.20. The firm’s 50-day moving average price is $19.88 and its 200 day moving average price is $16.36.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, February 12th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. 10x Genomics had a negative net margin of 6.77% and a negative return on equity of 6.89%. The company had revenue of $166.03 million during the quarter, compared to the consensus estimate of $160.35 million. During the same quarter in the prior year, the firm earned ($0.40) EPS. 10x Genomics’s quarterly revenue was up .6% on a year-over-year basis. As a group, analysts predict that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on TXG. UBS Group raised their price objective on 10x Genomics from $14.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, February 20th. Wall Street Zen cut shares of 10x Genomics from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Piper Sandler upped their price objective on shares of 10x Genomics from $15.00 to $19.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 11th. Leerink Partners dropped their target price on shares of 10x Genomics from $22.00 to $20.00 and set a “market perform” rating on the stock in a research report on Tuesday, January 27th. Finally, JPMorgan Chase & Co. boosted their target price on shares of 10x Genomics from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Four equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $18.46.

Insider Activity at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 8,968 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $18.58, for a total transaction of $166,625.44. Following the transaction, the chief financial officer owned 288,417 shares of the company’s stock, valued at approximately $5,358,787.86. The trade was a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Benjamin J. Hindson sold 7,826 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $18.58, for a total value of $145,407.08. Following the completion of the sale, the insider owned 424,779 shares of the company’s stock, valued at approximately $7,892,393.82. The trade was a 1.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 26,426 shares of company stock valued at $490,995. 9.39% of the stock is currently owned by insiders.

10x Genomics Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.